- Current report filing (8-K)
July 23 2012 - 6:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): July 17, 2012
ALSERES PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
|
Delaware
|
|
0-6533
|
|
87-0277826
|
|
(State or Other Jurisdiction
of Incorporation
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
239 South Street, Hopkinton, Massachusetts
|
|
01748
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (508) 497-2360
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
TABLE OF CONTENTS
-2-
Item 1.01. Entry into Material Definitive Agreements.
On July 17, 2012 the Company issued to Robert L. Gipson (the “Holder”) an unsecured promissory note, pursuant to which the
Company borrowed an aggregate principal amount of $150,000 (the Note”). Interest on the Note shall accrue at the rate of 7% per annum and all principal and accrued interest shall be due and payable on demand of the Holder.
The foregoing description of the Agreement and the Note are qualified in their entirety by the full text of the Note, a complete copy of
which is filed herewith as Exhibit 10.7 and is incorporated herein by reference.
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Alseres Pharmaceuticals, Inc.
|
|
|
|
|
|
|
Date: July 23, 2012
|
|
|
|
By:
|
|
/s/ Kenneth L. Rice, Jr.
|
|
|
|
|
|
|
|
Kenneth L. Rice, Jr.
|
|
|
|
|
|
|
|
Executive Vice President, Finance and Administration and Chief Financial Officer
|
-3-
EXHIBIT INDEX
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
10.7
|
|
Promissory Note dated July 17, 2012
|
-4-
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Oct 2024 to Nov 2024
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Nov 2023 to Nov 2024
